Abstract 407P
Background
The benefit of focal treatments, including surgery and radiotherapy, in mSTS patients has not been clear, especially for mSTS patients who had received systemic treatments.
Methods
Medical records of mSTS patients treated at National Taiwan University Hospital from 2011 to 2017 were collected. The focal tx collected included surgery (either for the primary or metastatic tumors) and radiation therapy (RT). The analysis was limited to patients who had received at least one-line of systemic treatment. Overall survival (OS) was measured from the time of mSTS diagnosis to the date of death or the last follow-up, whichever is later.
Results
A total of 199 patients, 78 (39%) de novo and 121 (61%) recurrent, mSTS were identified. The median age was 55 (range 20-89) and male to female ratio was 0.86. The most common histologies are leiomyosarcoma (16.5%), liposarcoma (15.6%), and sarcoma NOS (15.6%). Of them, 72 (36.2%) and 48 (24.1%) patients received surgery and RT, respectively. Metastatic STS patients who had received surgical treatment had a significantly better OS as compared with those who did not (median OS 21.9 vs 16.5 months, p = 0.0296). There was a trend that the OS benefit of surgery was mostly in patients with recurrence but not de novo mSTS (p for interaction = 0.08). The type of surgery (primary vs metastatic vs primary + metastatic) did not significantly affect OS (p = 0.608). Patients who received RT had a numerically better survival (median OS 24.4 vs 16.9 months, p = 0.12). In the multivariate Cox model, the OS benefit of surgery remained significant (Table).Table:
407P Adjusted hazard ratio of OS for mSTS patients who received palliative systemic treatment
HR | 95% CI | p-value | |
---|---|---|---|
Female vs male | 1.22 | (0.85, 1.76) | 0.2852 |
Age | 1.01 | (1.00, 1.02) | 0.0830 |
Histology | |||
Other | 1 | 0.0436 | |
Leiomyosarcoma + Liposarcoma | 0.65 | (0.43, 0.99) | |
Anthracycline | 1.63 | (1.12, 2.37) | 0.0109 |
Focal treatment | 0.0731 | ||
No focal treatment | 1 | ||
RT | 0.62 | (0.36, 1.08) | 0.0923 |
Surgery | 0.63 | (0.40, 0.99) | 0.0452 |
RT + Surgery | 0.55 | (0.30, 1.00) | 0.0502 |
Conclusions
Patients with mSTS had improved OS with focal treatments, especially with surgery. A multi-disciplinary team approach to include the surgeons and radiation oncologists to discuss the optimal treatment of mSTS patients should be advocated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Eli Lilly and Company.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract